Literature DB >> 8616512

Bidirectional modulation of mouse natural killer cell and macrophage cytotoxic activities by enkephalins.

J Kowalski1, D Belowski, J Wielgus.   

Abstract

Stimulation of a cellular immune function as measured by splenic natural killer (NK) cell activity has been described following systemic treatment with enkephalins. In this study, we evaluated the effects of the central administration of enkephalins on the splenic NK cell activity and macrophage cytotoxicity. Intracerebroventricular injection of leucine-enkephalin (LE) or methionine-enkephalin (ME) induced bidirectional modulation of NK cell and macrophage cytotoxic activities (suppression followed by enhancement). Administration of ME or LE at doses of 100 or 10 micrograms/mouse caused inhibition of NK cell and macrophage activity 2 h after injection. Enhancement of NK cells activity was observed at 96 h and macrophages cytotoxicity at 24 h after icv injection with both enkephalins. Pretreatment with naloxone (20 micrograms/mouse) inhibited the enkephalins-induced augmentation of NK cell and macrophage cytotoxic activity. These findings demonstrate that central actions of enkephalins produce changes in cytotoxicity of NK cells and macrophages.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8616512

Source DB:  PubMed          Journal:  Pol J Pharmacol        ISSN: 1230-6002


  2 in total

1.  Comparison of stimulating effect on subpopulations of lymphocytes in human peripheral blood by methionine enkephalin with IL-2 and IFN-γ.

Authors:  Hui Hua; Changlong Lu; Weiwei Li; Jingjuan Meng; Danan Wang; Nicolas P Plotnikoff; Enhua Wang; Fengping Shan
Journal:  Hum Vaccin Immunother       Date:  2012-08-01       Impact factor: 3.452

2.  The novel mechanism of anticancer effect on gastric cancer through inducing G0/G1 cell cycle arrest and caspase-dependent apoptosis in vitro and in vivo by methionine enkephalin.

Authors:  Xiaonan Wang; Jing Tian; Xue Jiao; Jin Geng; Reizhe Wang; Ning Liu; Xinghua Gao; Noreen Griffin; Yuan Gao; Fengping Shan
Journal:  Cancer Manag Res       Date:  2018-10-18       Impact factor: 3.989

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.